NCT05288881View on ClinicalTrials.gov

Single Ascending Dose Study of ANX105

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

June 19, 2023

Study Completion Date

June 19, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

ANX105

Participants will receive single-ascending doses of ANX105 administered by IV infusion.

DRUG

Placebo

Participants will receive matching placebo administered by IV infusion.

Trial Locations (2)

Unknown

Annexon Investigational Site 02, Groningen

Annexon Investigational Site 01, Leiden

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY